Nuvalent NUVL 深 沪
等待开盘 08-06 09:30:00 美东时间
123.96
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 123.96
- 总市值 98.09亿
- 52周最高 123.99
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 71.13
- 委 比 0.00%
- 总股本 7912.82万
- 历史最高 123.99
- 量 比 0
- 振 幅 0.00%
- 历史最低 7.09
- 每 手 1
- 风险率 13.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多GSK declares $0.4518/ADS or 17p/share dividend
GSK (GSK) declares approx. $0.4518 per ADS or 17.00p/share interim dividend, in line with previous, bringing total dividend declared to 70p/share for full year 2026. Payable Oct. 8; for shareholders o...
07-28 20:34
GSK announces $2.5B cost savings program to fund R&D
With its consensus-beating Q2 2026 results on Tuesday, GSK (GSK) announced a three-year program to reduce annual expenditure by £1.9B ($2.5B) in a bid to fund investment in its late-stage pipeline and...
07-28 20:01
GSK Non-GAAP EPS of £0.51 beats by £0.02, revenue of £8.41B beats by £4.05B; reaffirms FY2026 outlook
GSK press release (GSK): Q2 Non-GAAP EPS of £0.51 beats by £0.02. Revenue of £8.41B (+5.3% Y/Y) beats by £4.05B. Specialty Medicines sales £3.8 billion (+14%); Respiratory, Immunology & Inflammation £...
07-28 19:24
ViiV's Dovato as effective as Gilead's Biktarvy in head-to-head trial
ViiV Healthcare, which is majority owned by GSK (GSK), said that a head-to-head study of its HIV treatment Dovato (dolutegravir/lamivudine), which contains two drugs, is as effective as Gilead Science...
07-28 01:44
GSK Wins FDA Approval For Jideytro To Treat Previously Treated ROS1-Positive Non-Small Cell Lung Cancer
GSK plc (LSE/NYSE:GSK) today announced the US Food and Drug Administration (FDA) has approved Jideytro (zidesamtinib), a ROS1 selective inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase...
07-23 00:41
Trevi climbs after late-stage trial setback for GSK cough therapy
After GSK (GSK) announced it would discontinue a chronic cough therapy following a late-stage trial failure, Trevi Therapeutics (TRVI), which is advancing a rival candidate, traded higher to reach an ...
07-18 02:04
Q32 Bio prices $200M equity raise
Q32 Bio (QTTB) priced an underwritten public offering expected to raise approximately $200M in gross proceeds. The clinical-stage biotechnology company is offering 6.03M shares of common stock at $18....
07-15 14:22
GSK's Jemperli hits goal in phase 2 trial for rectal cancer
GSK (GSK) said that interim results from the phase 2 AZER-1 trial showed that patients with a certain type of rectal cancer given Jemperli (dostarlimab) showed a sustained complete clinical response r...
07-14 07:16
Cue Biopharma names Dominic Borie as CMO and head of R&D
Cue Biopharma (CUE) has appointed Dominic Borie as Chief Medical Officer and head of research & development. Borie brings more than two decades of experience leading research and clinical development ...
07-13 21:11
